Cabazitaxel

Generic Name: Cabazitaxel

Brand Names: Jevtana, Cabazitaxel Accord

Drug Type: Small Molecule

Chemical Formula: C_₄₅H_₅₇NO_₁₄

CAS Number: 183133-96-2

Unique Ingredient Identifier: 51F690397J

Background: Cabazitaxel is a taxoid synthesized from 10-deacetylbaccatin III, a compound isolated from the yew tree. As a second-generation semisynthetic microtubule inhibitor, cabazitaxel stabilizes microtubules and induces tumour cell death. Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more readily penetrate the blood–brain barrier compared to other taxanes like paclitaxel and docetaxel.

Cabazitaxel is used to treat metastatic castration-resistant prostate cancer. It was first approved by the FDA on June 17, 2010. It was also approved by the EMA on March 17, 2011 and Health Canada on December 17, 2019.

Indication: 用于治疗转移性去势抵抗性前列腺癌患者。

Associated Conditions: Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Clinical Trials

Evaluation of Cabazitaxel in Patients With Brain Metastasis Secondary to Breast Cancer and NSCLC

Phase 2

Withdrawn

Conditions: Non Small Cell Lung Cancer
Brain Metastasis
Breast Cancer

Interventions: Drug: Cabazitaxel
Procedure: Contrast-enhanced whole brain MRI

First Posted Date: 2013-07-31

Last Posted Date: 2014-07-24

Lead Sponsor: Jules Bordet Institute

Registration Number: NCT01913067

Locations: 🇧🇪
Institut Jules Bordet, Brussels, Belgium

Prospective Phase 2 Trial of Cabazitaxel in Patients With Temozolomide Refractory Glioblastoma Multiforme

Phase 2

Completed

Conditions: Glioblastoma Multiforme (GBM) WHO Grade IV

Interventions: Drug: Cabazitaxel

First Posted Date: 2013-05-31

Last Posted Date: 2017-10-26

Lead Sponsor: University of Ulm

Target Recruit Count: 24

Registration Number: NCT01866449

Locations: 🇩🇪
Lars Bullinger, MD, Ulm, Germany
🇩🇪
Hämatologisch onkologische Praxis, Augsburg, Germany
🇩🇪
Stiftungsklinikum Mittelrhein GmbH, Koblenz, Germany

Cabazitaxel in Relapsed and Metastatic NSCLC

Phase 2

Completed

Conditions: NSCLC

Interventions: Drug: Cabazitaxel

First Posted Date: 2013-05-13

Last Posted Date: 2015-09-28

Lead Sponsor: Hellenic Oncology Research Group

Target Recruit Count: 46

Registration Number: NCT01852578

Locations: 🇬🇷
"Ag. Georgios" General Hospital of Chania, Chania, Crete, Greece
🇬🇷
"IASO" General Hospital of Athens Athens, Greece, Athens, Greece
🇬🇷
Air Forces Military Hospital of Athens Athens, Greece, Athens, Greece

and more 2 locations

Study of Abiraterone Acetate and Prednisone in Combination With Cabazitaxel in Patients With Prostate Cancer

Phase 2

Terminated

Conditions: Prostate Cancer

Interventions: Drug: Cabazitaxel with Abiraterone Acetate
Drug: Cabazitaxel

First Posted Date: 2013-05-03

Last Posted Date: 2018-06-04

Lead Sponsor: University of Colorado, Denver

Target Recruit Count: 7

Registration Number: NCT01845792

Locations: 🇺🇸
University of Colorado Cancer Center, Aurora, Colorado, United States

Cabazitaxel vs. Vinflunine in Metastatic or Locally Advanced Transitional Cell Carcinoma of the Urothelium (TCCU)

Phase 2

Conditions: Urothelium Transitional Cell Carcinoma

Interventions: Drug: Cabazitaxel
Drug: Vinflunine

First Posted Date: 2013-04-12

Last Posted Date: 2014-01-28

Lead Sponsor: Associació per a la Recerca Oncologica, Spain

Target Recruit Count: 372

Registration Number: NCT01830231

Locations: 🇳🇱
St. Antoniusziekenhuis, Nieuwegein, Netherlands
🇳🇱
Vumc Amsterdam, Amsterdam, Netherlands
🇳🇱
NKI-AvL, Amsterdam, Netherlands

and more 17 locations

Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma

Phase 2

Completed

Conditions: Gastroesophageal Adenocarcinoma
Gastric Adenocarcinoma
Distal Esophageal Adenocarcinoma

Interventions: Drug: Cabazitaxel

First Posted Date: 2012-12-28

Last Posted Date: 2018-04-03

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 85

Registration Number: NCT01757171

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸
UCSF Comprehensive Cancer Center, San Francisco, California, United States

and more 2 locations

A Dose Finding Study of XRP6258 in Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Advanced Solid Tumor

Interventions: Drug: Cabazitaxel (XRP6258)

First Posted Date: 2012-12-24

Last Posted Date: 2012-12-24

Lead Sponsor: Sanofi

Target Recruit Count: 42

Registration Number: NCT01755390

Locations: 🇪🇸
Sanofi, Barcelona, Spain

Cabazitaxel in Men 75 Years of Age or Older With Castration-Resistant Prostate Cancer

Phase 2

Withdrawn

Conditions: Castrate-resistant Metastatic Prostate Cancer

Interventions: Drug: Cabazitaxel
Drug: Prednisone
Drug: Granulocyte colony-stimulating factor (G-CSF)

First Posted Date: 2012-12-17

Last Posted Date: 2013-10-16

Lead Sponsor: Case Comprehensive Cancer Center

Registration Number: NCT01750866

Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors

Phase 1

Completed

Conditions: Malignant Solid Tumor - Malignant Nervous System Neoplasm

Interventions: Drug: Cabazitaxel (XRP6258)

First Posted Date: 2012-12-17

Last Posted Date: 2016-08-12

Lead Sponsor: Sanofi

Target Recruit Count: 39

Registration Number: NCT01751308

Locations: 🇺🇸
Investigational Site Number 840005, Orlando, Florida, United States
🇺🇸
Investigational Site Number 840014, Palo Alto, California, United States
🇨🇦
Investigational Site Number 124001, Toronto, Canada

and more 10 locations

Cabazitaxel in Platinum Refractory Ovarian Cancer

Phase 2

Terminated

Conditions: Ovarian Cancer

Interventions: Drug: Cabazitaxel

First Posted Date: 2012-12-11

Last Posted Date: 2014-12-04

Lead Sponsor: Vejle Hospital

Target Recruit Count: 4

Registration Number: NCT01747239

Locations: 🇩🇰
Herlev Hospital, Herlev, Denmark
🇩🇰
Department of Oncology, Aalborg Hospital, Aalborg, Denmark
🇩🇰
Department of Oncology, Odense University Hospital, Odense, Denmark

and more 1 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy